Journal of Cell Science & Therapy
Open Access
ISSN: 2157-7013
+44 1300 500008
ISSN: 2157-7013
+44 1300 500008
Xu Shi-xia, Xu Hai-qin, Feng Bo, Tang Xian-hua and Tang Xiang-feng
Accepted Abstracts: J Cell Sci Ther
Th e reduced intensity conditioning (RIC) stem cell transplantation is widely used for treatment of many hematologic malignancies. Th is study was undertaken to determine if any signifi cant diff erence could be found respectively by using RIC versus myeloablative conditioning (MAC) regimen for transplantation on myeloid and lymphoid malignancies and provided the comparison on outcomes in survival and complications. Methods: We electronically searched the database of Cochrane Central Register of Controlled Trials (CENTRAL), Pubmed, EMbase, and critically appraised all relevant articles (1987.01?2011.03). Comparative studies were carried out on clinical therapeutic eff ect of RIC and MAC with research on survival, GVHD, relapse, and transplantation related complications (TRM). Meta-analysis was performed by Review Manager 5.0.0.32 soft ware and the funnel plot regression was adopted to assess the publication bias. Results: We get 1710 records, and 12 studies contained 6 for myeloid malignancies and 6 for lymphoid malignancies totaling 4240 patients have been included. Pooled comparisons of studies of RIC and MAC in transplantation found that diff erent diseases and diff erent conditioning regimen had impact on the outcome. For both myeloid and lymphoid malignancies, compared with MAC regimen, the RIC regimen had signifi cantly lower incidences of TRM (OR=0.56 and 0.52 respectively, P<0.001), higher relapse rates (OR=1.85 and 3.16 respectively, P<0.001) and lower rates of DFS (OR=0.72 and 0.67 respectively, P<0.05), but the overall survival (OS) is similar between the 2 regimens. Patients with myeloid malignancies had signifi cantly lower rates of relapse, higher rates of ≥II degree aGVHD and cGVHD than patients with lymphoid malignancies, and the two types of malignancies have similar rates of DFS. Conclusions: Th is meta-analysis confi rmed that diff erent regimen has diff erent eff ect on the outcome and proposed regimen selection for treatment of hematologic malignancies.